# Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

> **NCT05618028** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 78 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- B Cell Malignancies
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** ABBV-525

## Key facts

- **NCT ID:** NCT05618028
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-04
- **Primary completion:** 2029-07
- **Final completion:** 2029-07
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618028, "Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05618028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*